|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CBLB |
Gene summary for CBLB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CBLB | Gene ID | 868 |
| Gene name | Cbl proto-oncogene B | |
| Gene Alias | Cbl-b | |
| Cytomap | 3q13.11 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q13191 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 868 | CBLB | CCI_2 | Human | Cervix | CC | 1.59e-04 | 7.81e-01 | 0.5249 |
| 868 | CBLB | CCI_3 | Human | Cervix | CC | 6.32e-16 | 9.84e-01 | 0.516 |
| 868 | CBLB | HTA11_5212_2000001011 | Human | Colorectum | AD | 5.04e-03 | -6.00e-01 | -0.2061 |
| 868 | CBLB | HTA11_866_3004761011 | Human | Colorectum | AD | 1.65e-03 | -3.32e-01 | 0.096 |
| 868 | CBLB | HTA11_8622_2000001021 | Human | Colorectum | SER | 3.64e-02 | -4.91e-01 | 0.0528 |
| 868 | CBLB | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.40e-23 | -6.20e-01 | 0.3005 |
| 868 | CBLB | A002-C-010 | Human | Colorectum | FAP | 2.20e-03 | 1.31e-01 | 0.242 |
| 868 | CBLB | A001-C-207 | Human | Colorectum | FAP | 8.74e-04 | 1.41e-01 | 0.1278 |
| 868 | CBLB | A015-C-203 | Human | Colorectum | FAP | 1.50e-27 | -2.52e-01 | -0.1294 |
| 868 | CBLB | A015-C-204 | Human | Colorectum | FAP | 1.34e-06 | -2.13e-01 | -0.0228 |
| 868 | CBLB | A014-C-040 | Human | Colorectum | FAP | 5.84e-05 | -2.28e-01 | -0.1184 |
| 868 | CBLB | A002-C-201 | Human | Colorectum | FAP | 3.42e-14 | -2.35e-01 | 0.0324 |
| 868 | CBLB | A002-C-203 | Human | Colorectum | FAP | 3.45e-03 | -1.10e-03 | 0.2786 |
| 868 | CBLB | A001-C-119 | Human | Colorectum | FAP | 6.83e-07 | -4.03e-01 | -0.1557 |
| 868 | CBLB | A001-C-108 | Human | Colorectum | FAP | 4.53e-16 | -2.54e-01 | -0.0272 |
| 868 | CBLB | A002-C-021 | Human | Colorectum | FAP | 4.58e-03 | 3.65e-01 | 0.1171 |
| 868 | CBLB | A002-C-205 | Human | Colorectum | FAP | 7.28e-25 | -3.41e-01 | -0.1236 |
| 868 | CBLB | A001-C-104 | Human | Colorectum | FAP | 1.95e-02 | -7.98e-02 | 0.0184 |
| 868 | CBLB | A015-C-006 | Human | Colorectum | FAP | 2.64e-18 | -5.08e-01 | -0.0994 |
| 868 | CBLB | A015-C-106 | Human | Colorectum | FAP | 1.13e-10 | -2.41e-01 | -0.0511 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
| GO:004573210 | Cervix | CC | positive regulation of protein catabolic process | 65/2311 | 231/18723 | 7.44e-11 | 1.39e-08 | 65 |
| GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
| GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
| GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
| GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
| GO:003139610 | Cervix | CC | regulation of protein ubiquitination | 59/2311 | 210/18723 | 5.90e-10 | 7.51e-08 | 59 |
| GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
| GO:00508638 | Cervix | CC | regulation of T cell activation | 80/2311 | 329/18723 | 1.28e-09 | 1.47e-07 | 80 |
| GO:00071598 | Cervix | CC | leukocyte cell-cell adhesion | 85/2311 | 371/18723 | 8.27e-09 | 7.07e-07 | 85 |
| GO:00071738 | Cervix | CC | epidermal growth factor receptor signaling pathway | 36/2311 | 108/18723 | 1.04e-08 | 8.44e-07 | 36 |
| GO:00071626 | Cervix | CC | negative regulation of cell adhesion | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
| GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
| GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
| GO:19030378 | Cervix | CC | regulation of leukocyte cell-cell adhesion | 77/2311 | 336/18723 | 4.08e-08 | 2.54e-06 | 77 |
| GO:00430877 | Cervix | CC | regulation of GTPase activity | 79/2311 | 348/18723 | 4.21e-08 | 2.60e-06 | 79 |
| GO:00381278 | Cervix | CC | ERBB signaling pathway | 37/2311 | 121/18723 | 8.57e-08 | 4.88e-06 | 37 |
| GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
| GO:005109810 | Cervix | CC | regulation of binding | 80/2311 | 363/18723 | 1.32e-07 | 6.42e-06 | 80 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0412018 | Prostate | BPH | Ubiquitin mediated proteolysis | 61/1718 | 142/8465 | 5.50e-10 | 9.07e-09 | 5.61e-09 | 61 |
| hsa0414425 | Prostate | BPH | Endocytosis | 89/1718 | 251/8465 | 1.06e-08 | 1.29e-07 | 7.99e-08 | 89 |
| hsa049107 | Prostate | BPH | Insulin signaling pathway | 43/1718 | 137/8465 | 1.34e-03 | 5.81e-03 | 3.60e-03 | 43 |
| hsa051624 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
| hsa0401214 | Prostate | BPH | ErbB signaling pathway | 28/1718 | 85/8465 | 4.12e-03 | 1.45e-02 | 8.95e-03 | 28 |
| hsa0412019 | Prostate | BPH | Ubiquitin mediated proteolysis | 61/1718 | 142/8465 | 5.50e-10 | 9.07e-09 | 5.61e-09 | 61 |
| hsa04144111 | Prostate | BPH | Endocytosis | 89/1718 | 251/8465 | 1.06e-08 | 1.29e-07 | 7.99e-08 | 89 |
| hsa0491012 | Prostate | BPH | Insulin signaling pathway | 43/1718 | 137/8465 | 1.34e-03 | 5.81e-03 | 3.60e-03 | 43 |
| hsa0516211 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
| hsa0401215 | Prostate | BPH | ErbB signaling pathway | 28/1718 | 85/8465 | 4.12e-03 | 1.45e-02 | 8.95e-03 | 28 |
| hsa0412024 | Prostate | Tumor | Ubiquitin mediated proteolysis | 61/1791 | 142/8465 | 3.08e-09 | 5.09e-08 | 3.16e-08 | 61 |
| hsa0414426 | Prostate | Tumor | Endocytosis | 92/1791 | 251/8465 | 7.83e-09 | 1.04e-07 | 6.43e-08 | 92 |
| hsa0491022 | Prostate | Tumor | Insulin signaling pathway | 44/1791 | 137/8465 | 1.69e-03 | 7.10e-03 | 4.40e-03 | 44 |
| hsa051622 | Prostate | Tumor | Measles | 44/1791 | 139/8465 | 2.33e-03 | 8.85e-03 | 5.49e-03 | 44 |
| hsa0401222 | Prostate | Tumor | ErbB signaling pathway | 27/1791 | 85/8465 | 1.43e-02 | 4.30e-02 | 2.67e-02 | 27 |
| hsa0412034 | Prostate | Tumor | Ubiquitin mediated proteolysis | 61/1791 | 142/8465 | 3.08e-09 | 5.09e-08 | 3.16e-08 | 61 |
| hsa0414435 | Prostate | Tumor | Endocytosis | 92/1791 | 251/8465 | 7.83e-09 | 1.04e-07 | 6.43e-08 | 92 |
| hsa0491032 | Prostate | Tumor | Insulin signaling pathway | 44/1791 | 137/8465 | 1.69e-03 | 7.10e-03 | 4.40e-03 | 44 |
| hsa051623 | Prostate | Tumor | Measles | 44/1791 | 139/8465 | 2.33e-03 | 8.85e-03 | 5.49e-03 | 44 |
| hsa0401232 | Prostate | Tumor | ErbB signaling pathway | 27/1791 | 85/8465 | 1.43e-02 | 4.30e-02 | 2.67e-02 | 27 |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CBLB | SNV | Missense_Mutation | c.422G>A | p.Arg141Gln | p.R141Q | Q13191 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| CBLB | SNV | Missense_Mutation | c.1753N>A | p.Asp585Asn | p.D585N | Q13191 | protein_coding | tolerated_low_confidence(0.06) | benign(0.001) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| CBLB | SNV | Missense_Mutation | rs748390313 | c.2200N>T | p.Arg734Trp | p.R734W | Q13191 | protein_coding | tolerated_low_confidence(0.06) | probably_damaging(0.936) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CBLB | SNV | Missense_Mutation | novel | c.68N>G | p.Leu23Trp | p.L23W | Q13191 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CBLB | SNV | Missense_Mutation | c.229N>G | p.Ile77Val | p.I77V | Q13191 | protein_coding | deleterious(0.02) | possibly_damaging(0.876) | TCGA-AO-A03L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
| CBLB | SNV | Missense_Mutation | c.769C>T | p.His257Tyr | p.H257Y | Q13191 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| CBLB | SNV | Missense_Mutation | c.952N>G | p.Gln318Glu | p.Q318E | Q13191 | protein_coding | deleterious(0) | possibly_damaging(0.833) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| CBLB | SNV | Missense_Mutation | c.1210G>A | p.Asp404Asn | p.D404N | Q13191 | protein_coding | deleterious(0.04) | probably_damaging(0.95) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR | |
| CBLB | SNV | Missense_Mutation | c.2483C>T | p.Ala828Val | p.A828V | Q13191 | protein_coding | tolerated_low_confidence(0.4) | benign(0.116) | TCGA-BH-A0C1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| CBLB | SNV | Missense_Mutation | c.1073N>G | p.Glu358Gly | p.E358G | Q13191 | protein_coding | deleterious(0) | benign(0.241) | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 868 | CBLB | CLINICALLY ACTIONABLE, ENZYME | Fasudil | FASUDIL | 26177294 | |
| 868 | CBLB | CLINICALLY ACTIONABLE, ENZYME | Fluorouracil | FLUOROURACIL | 24351824 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |